Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 412

1.

[Clinical efficacy of enzyme replacement therapy in Fabry disease. A critical review].

Lidove O, Papo T.

Rev Med Interne. 2009 Oct;30(10):920-9. doi: 10.1016/j.revmed.2009.04.003. Epub 2009 Jun 12. Review. French.

PMID:
19524334
2.

Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature.

Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T.

Int J Clin Pract. 2007 Feb;61(2):293-302. Review.

PMID:
17263716
3.

Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Schaefer RM, Tylki-Szymańska A, Hilz MJ.

Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. Review.

PMID:
19852524
4.

Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.

Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A.

Genet Med. 2010 Nov;12(11):668-79. doi: 10.1097/GIM.0b013e3181f13b75. Review.

PMID:
20962662
5.

The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.

Morel CF, Clarke JT.

Expert Opin Biol Ther. 2009 May;9(5):631-9. doi: 10.1517/14712590902902296 . Review.

PMID:
19368525
6.

Fabry disease: overall effects of agalsidase alfa treatment.

Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A.

Eur J Clin Invest. 2004 Dec;34(12):838-44.

PMID:
15606727
7.

Enzyme replacement therapy of Fabry disease.

Clarke JT, Iwanochko RM.

Mol Neurobiol. 2005 Aug;32(1):43-50. Review.

PMID:
16077182
8.

Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.

Caballero L, Climent V, Hernández-Romero D, Quintanilla MA, de la Morena G, Marín F.

Curr Med Chem. 2010;17(16):1679-89. Review.

PMID:
20345350
9.

Agalsidase alfa: a review of its use in the management of Fabry disease.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):335-54. doi: 10.2165/11209690-000000000-00000. Review.

PMID:
22946754
10.

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators.

J Med Genet. 2005 Mar;42(3):247-52.

11.

Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters.

Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E, Penttinen M, Knuuti J, Mononen I, Kantola IM.

J Inherit Metab Dis. 2008 Jun;31(3):432-41. doi: 10.1007/s10545-008-0848-3. Epub 2008 May 23.

PMID:
18509742
12.

Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety.

Beck M.

Expert Opin Biol Ther. 2009 Feb;9(2):255-61. doi: 10.1517/14712590802658428 . Review.

PMID:
19236256
13.

Treatment with agalsidase beta during pregnancy in Fabry disease.

Politei JM.

J Obstet Gynaecol Res. 2010 Apr;36(2):428-9. doi: 10.1111/j.1447-0756.2009.01164.x.

PMID:
20492401
14.

Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.

Mignani R, Cagnoli L.

J Nephrol. 2004 May-Jun;17(3):354-63. Review.

PMID:
15365954
15.

Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.

Thofehrn S, Netto C, Cecchin C, Burin M, Matte U, Brustolin S, Nunes AC, Coelho J, Tsao M, Jardim L, Giugliani R, Barros EJ.

Ren Fail. 2009;31(9):773-8. doi: 10.3109/08860220903150296.

PMID:
19925283
16.

[Effect of enzyme replacement therapy (ERT) on renal function of patients with Fabry's disease].

Thomaidis T, Relle M, Reinke J, Beck M, Schwarting A.

Med Klin (Munich). 2009 Sep 15;104(9):699-703. doi: 10.1007/s00063-009-1152-1. Epub 2009 Sep 23. Review. German.

PMID:
19779674
17.

Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease.

Beck M.

Expert Opin Investig Drugs. 2002 Jun;11(6):851-8. Review.

PMID:
12036428
18.

Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study.

Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, Marmo M, Liuzzi R, Visciano B, Cianciaruso B, Salvatore M.

Heart. 2009 Jul;95(13):1103-7. doi: 10.1136/hrt.2008.162800. Epub 2009 Apr 15.

PMID:
19372091
19.

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.

Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB.

Heart. 2008 Feb;94(2):153-8. Epub 2007 May 4.

PMID:
17483124
20.

[Development of an orphan drug to treat a genetic disease: the paradigm of agalsidase beta].

Germain DP, Benistan K.

Presse Med. 2007 Mar;36 Spec No 1:1S69-75. Review. French.

PMID:
17546772
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk